Theralink Technologies Inc. · OTC:THER
Theralink Technologies — OncBioMune Pharmaceuticals — Investor Presentation (August 2020)
32 slides from Theralink Technologies's investor presentation, Aug 26, 2020
Slide 1: Theralink Technologies Investor Presentation
3'™; THERALIN K* at Precision Medicine for Life” OncBioMune d/b/a Theralink Technologies (OTC: OBMP) Investor Presentation Enabling Phy:
Slide 2: Disclaimers
a Disclaimers Siren ipectatons and pojecions rbot the Companys Mitre reruta. petormarce Loui, faneal conation prospects and opporurites nd at based upor ‘Sormaton caren siiabe tthe Company anther managemer= ane the interpretation a what ae ese to oe nga ar secing our busters Lang Inany nome regardin
Slide 3: Topics
Topics 1. Theralink Technologies Overview 2. The Current State of Cancer Market and Opportunity 3 4. Core Technology wt Robust and Growing IP Competition Growth Strategy Management and Leadership Team oe NO 2020 Milestones 10. Investment Highlights SQ) THERALINK™
Slide 4: Theralink Technologies Overview
Theralink® Technologies Overview RPPA technology measures activated proteins, which are the primary targets of many RPPA Technology FDA-approved therapies and investigational drugs. Theralink is the only Company with patented, proteomic, data-generating RPPA technology. A robust patent portfolio, co
Slide 5: What Does Theralink's Technologies Have in Common with the Following Institutions?
What does Theralink’s Technologies Have in Common with the Following 20 Domestic and International Institutions that are Utilizing our RPPA Technology in their Basic Research? Proven Technology United States Europe Asia Pacific + 7Commercial A George Mason University Royal College of Surgeons, irela
Slide 6: What Makes Theralink Technologies Unique?
What Makes Theralink Technologies Unique? Theralink Technologies is the only Company that combines laser capture microdissection with patented data-generating RPPA technology to quantify active protein signaling in the cell using minimal sample input. bk at Dah Genomics Transcriptomics Proteomics Ph
Slide 7: Theralink's Reverse Phase Protein Array (RPPA) Technology
aaa Theralink’s Reverse Phase Protein Array (RPPA) Technology Beyond Genomics...Changing the Paradigm in Cancer Treatment * Developed by the founding scientists at the world-renowned Center for Applied Proteomics and Molecular Medicine at George Mason University. * Theralink’s RPPA technology can me
Slide 8: The Current State of Cancer
The Current State of Cancer * Cancer is heterogeneous and each patient’s cancer is UNIQUE. * Cancer is a disease of abnormal protein signaling, and many therapeutic drugs target these aberrant proteins. * Theralink assesses which proteins are likely driving a patient’s cancer. * Not all drugs work f
Slide 9: The Power of Phosphoproteomics
SR THERALINK The Power of Phosphoproteomics Genomics/Transcriptomics The “Instructions” + Information is not directly actionable as drugs : target proteins, not genes or transcripts *+ Transcript (RNA) levels do not correlate with : the levels of expressed and a protein + Leads to indirect predi or
Slide 10: The Value of RPPA
i The Value of RPPA For Drug Companies For Patients Accelerate drug discovery Advanced therapy selection and development for potential improvements in therapeutic response the next level of Precision Medi SQ THERALINK 10
Slide 11: Market Size
Market Size Number of Clinical Trials Incidence of Cancer (U.S.) U.S. Market Analysis (TAM, SAM, SOM) +2 TAM: Worldwide TAM: US ‘SAM: US Only 98,745 Ko) + Theralink® could potentially improve the management of over 800,000 ¢ cancer patients in the US alone after planned expansion to pancreatic cance
Slide 12: Commercial Opportunity: Precision Medicine
Commercial Opportunity: Precision Medicine Opportunities Total Market * Match patients to trial + Improve effectiveness & reduce costs $1 Billion * Increase success of drug approvals Biopharma Clinical Trial (near-term) * Treatment selection with Theralink Assay Oncologist Drug * More accurately pre
Slide 13: Initial Commercialization Strategy: Silos
aaa Initial Commercialization Strategy: 2 Silos Theralink Business Markets Precision Oncology/ oe SVS IELME SSIES Clinical Testing * Drug Development * Theralink Clinical Assay * Companion Diagnostics * CAP/CLIA Lab (CDx) Development SQ) THERALINK™ 3B
Slide 14: Initial Commercialization Strategy: Biopharma Services
aaa Initial Commercialization Strategy: Silo 1 Biopharma Services Helping drug companies accelerate discovery and development of novel cancer treatments THERALINK™ 4
Slide 15: Biopharma R&D: Our Core Technology Works Across Continuum
Biopharma R&D: Our Core Technology Works Across Continuum tea tesa ey) Recarence Discovery Clinical Trials Patient Care + Provides Biopharma companies in + Provides Biopharma companies in * Provides on label, marketed CDx the preclinical stage the ability to _the clinical stage the ability to (inclu
Slide 16: Theralink: Biopharma LCM/RPPA Workflow
Theralink: Biopharma LCM/RPPA Workflow Heterogenous Tumor cells Proteins measured Reverse Phase Antibody Probe Informatics Protein Array and Staining Report 16
Slide 17: Initial Commercialization Strategy: Precision Oncology/Clinical Testing
THERALINK™ Initial Commercialization Strategy: Silo 2 Precision Oncology/ Clinical Testing Providing actionable information on activity of key drug targets in oncology v7
Slide 18: Precision Oncology Care: Theralink Clinical Assay
Precision Oncology Care: Theralink Clinical Assay * Theralink measures the presence and activation status of the drug targets. * While genomic analysis can reveal gene mutations, it can not directly measure the abundance of activated protein. * The drug will only work if the drug target is actively
Slide 19: Theralink: Clinical Assay Workflow
SQ) THERALINK™ Theralink: Clinical Assay Workflow para pay pay ay. DAY 6. Day 5. pay 19
Slide 20: Companion Diagnostics to Advance Precision Oncology
aaa Companion Diagnostics to Advance Precision Oncology CDx is a Core Component of Both Business Markets * A Companion Diagnostic (CDx) is a test that must be ordered by a physician/oncologist prior to the doctor prescribing the associated drug or targeted therapy. FDA expects contemporaneous regula
Slide 21: Benefits of Theralink
rf rd t $ SQ THERALINK Benefits of Theralink For Biopharma Companies * Reduce clinical trial failure rates and cost. * Increase efficacy rates that can support premium pricing. For Oncologists * Identifies treatment options. * Guides therapies for patients who develop resistance to treatment. For Pa
Slide 22: Robust and Growing IP and Patent Portfolio
Robust and Growing IP and Patent Portfolio Patent Title Patent Number mTOR Pathway Theralink Phosphorylated c-erbB2 As a Superior Predictive for Cancer Dx / Tx ‘Methods for Detecting and Controlling Cancer Combinatorial Therapy for Protein Signaling Diseases Tissue Preservation and Fixation Method S
Slide 23: Competitive Landscape: Only Complete Proteomics Company
Competitive Landscape: Only Complete Proteomics Company Feature End User at Drug Target Activation Mapping Biopharma Biopharma Activated Phosphoprotein Biomarkers . + Oncologists Biopharma Quantitative Protein Biomarkers + Oncologists Biopharma Qualitative Proteomic Markers i + Oncologists ++ ++ SQ)
Slide 24: Growth Strategy
aaa. Growth Strategy Biopharma Alliances: * Service and Leverage Current Clients * Sales Pipeline with numerous Global Biopharma Prospects + Recently hired Experienced Senior Director, Biopharma Commercial Operations. Continually pursue Companion Diagnostics with biopharmaceutical partners. CAP/CLIA
Slide 25: Growth Strategy (cont.)
aaa. Growth Strategy (ona) * Develop and deploy an informational marketing campaign coupled with increased funding to inform pharmaceutical companies, laboratory service providers, insurers, and clinicians/oncologists and their patients of the value that the Theralink assays might offer to their cli
Slide 26: What Experts Say About The Theralink Assay
aaa What EXPERTS Say About The Theralink Assay “The Theralink assay allows me to understand “We use the Theralink assay on every possible which protein biomarkers and signaling pathways occasion, in combination with targeted sequencing, are active and driving my patients metastatic to guide the choi
Slide 27: Experienced Leadership: Corporate
Experienced Leadership: Corporate Jeffrey Busch, Esq., Chairman co-founder, chairman and CEO of Giobal Medical REIT, Inc. (GMIRE), 2 NYSE lcted public company. Industry leader in building and sustaining medical companies worldwide ‘Mr. Busch was appointed by two US Presidents to serve in their Admin
Slide 28: Experienced Leadership: Commercialization
Experienced Leadership: Commercialization Trevor McCartney Senior Director of Business Development 20+ years of cancer leadership experience working in the field of enabling technologies for cancer care Various capacities with Elekta inc, 2 global provider of ‘medical devices forthe treatment of can
Slide 29: Scientific & Pathology Advisors
Scientific & Pathology Advisors Dr. Emanuel F. Petricoin Founder RPPA * Co-Director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University since 2005. * Co-founder of 4 life science companies, co- authored nearly 400 publications, co-inventor on 40 filed and p
Slide 30: 2020 Milestones
2020 Milestones CLIA Certification for Lab in Q4 2020 Planning 4 Cancer Center and Channel Partner Accounts Planning 5 Biopharma Contracts Roll out of Theralink’s Clinical Registry Trial for Reimbursement Begin receiving patient tumor samples from Oncologists SQ THERALINK 30
Slide 31: Investment Highlights
aaa. Investment Highlights Only Company with the commercial rights and licenses to this patented, proteomic, data-generating RPPA technology. Valuable IP portfolio (7 patents) Innovative platform technology that can Focused initially on breast cancer be leveraged for many large market Through R&D th
Slide 32: Theralink Technologies Contact
SQ THERALINK Theralink Technologies 15000 West 6" Ave, Suite 400 Golden, CO 80401 https://theralink.com/ Investor Contact: Valter Pinto / Allison Soss: KCSA Strategic Communications Phone: (212) 896-1254 Email: investors@theralink.com
OncBioMune Pharmaceuticals — Investor Presentation (August 2020) on 6ix